CN102525954A - 左旋棉酚及其醋酸盐的注射用冻干乳制剂 - Google Patents
左旋棉酚及其醋酸盐的注射用冻干乳制剂 Download PDFInfo
- Publication number
- CN102525954A CN102525954A CN2011103508676A CN201110350867A CN102525954A CN 102525954 A CN102525954 A CN 102525954A CN 2011103508676 A CN2011103508676 A CN 2011103508676A CN 201110350867 A CN201110350867 A CN 201110350867A CN 102525954 A CN102525954 A CN 102525954A
- Authority
- CN
- China
- Prior art keywords
- injection
- gossypol
- acetate
- levorotation
- levorotation gossypol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229950005277 gossypol Drugs 0.000 title claims abstract description 164
- 239000007924 injection Substances 0.000 title claims abstract description 93
- 238000002347 injection Methods 0.000 title claims abstract description 93
- 238000002360 preparation method Methods 0.000 title claims abstract description 57
- 239000000839 emulsion Substances 0.000 title claims abstract description 55
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 title claims abstract description 51
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 87
- 239000000203 mixture Substances 0.000 claims abstract description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 31
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 31
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 31
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 31
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 29
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 29
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000005642 Oleic acid Substances 0.000 claims abstract description 29
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 29
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 29
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 29
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 29
- 239000008215 water for injection Substances 0.000 claims abstract description 29
- 239000003921 oil Substances 0.000 claims abstract description 22
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 14
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 11
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 claims description 317
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 claims description 157
- 229930000755 gossypol Natural products 0.000 claims description 157
- 238000009472 formulation Methods 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 35
- 238000001035 drying Methods 0.000 claims description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- INGSNVSERUZOAK-UHFFFAOYSA-N ritalinic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C1CCCCN1 INGSNVSERUZOAK-UHFFFAOYSA-N 0.000 claims description 33
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 32
- 238000004108 freeze drying Methods 0.000 claims description 27
- 210000000481 breast Anatomy 0.000 claims description 26
- 210000003022 colostrum Anatomy 0.000 claims description 26
- 235000021277 colostrum Nutrition 0.000 claims description 26
- 239000012071 phase Substances 0.000 claims description 26
- 238000010792 warming Methods 0.000 claims description 26
- 235000012424 soybean oil Nutrition 0.000 claims description 24
- 239000003549 soybean oil Substances 0.000 claims description 24
- 235000019198 oils Nutrition 0.000 claims description 21
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 claims description 20
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 16
- 235000010265 sodium sulphite Nutrition 0.000 claims description 16
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 13
- 239000008346 aqueous phase Substances 0.000 claims description 13
- 238000007710 freezing Methods 0.000 claims description 13
- 230000008014 freezing Effects 0.000 claims description 13
- 238000000265 homogenisation Methods 0.000 claims description 13
- 239000010734 process oil Substances 0.000 claims description 13
- 238000012546 transfer Methods 0.000 claims description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 8
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 239000008347 soybean phospholipid Substances 0.000 claims description 6
- 239000001488 sodium phosphate Substances 0.000 claims description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 4
- 150000002168 ethanoic acid esters Chemical class 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- 229960000502 poloxamer Drugs 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 125000000647 trehalose group Chemical group 0.000 claims description 2
- NIOHNDKHQHVLKA-UHFFFAOYSA-N acetic acid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde Chemical compound CC(O)=O.CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 NIOHNDKHQHVLKA-UHFFFAOYSA-N 0.000 abstract description 5
- 239000002577 cryoprotective agent Substances 0.000 abstract 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 abstract 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 229940083466 soybean lecithin Drugs 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006340 racemization Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002583 male contraceptive agent Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
实施例1制剂 | 实施例2制剂 | 实施例5制剂 | 实施例7制剂 | 实施例10制剂 | |
生物利用度 | 89.3% | 87.0% | 81.8% | 79.5% | 72.4% |
组织 | 肿瘤 | 心 | 肝 | 脾 | 肺 | 肾 |
T值 | 16.7 | 5.2 | 8.4 | 6.1 | 2.9 | 4.6 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110350867 CN102525954B (zh) | 2011-11-09 | 2011-11-09 | 左旋棉酚及其醋酸盐的注射用冻干乳制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110350867 CN102525954B (zh) | 2011-11-09 | 2011-11-09 | 左旋棉酚及其醋酸盐的注射用冻干乳制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102525954A true CN102525954A (zh) | 2012-07-04 |
CN102525954B CN102525954B (zh) | 2013-06-05 |
Family
ID=46334788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110350867 Active CN102525954B (zh) | 2011-11-09 | 2011-11-09 | 左旋棉酚及其醋酸盐的注射用冻干乳制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102525954B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103202808A (zh) * | 2013-05-03 | 2013-07-17 | 西安电子科技大学 | 一种一锅法制备多功能棉酚纳米制剂的方法 |
CN111821288A (zh) * | 2020-05-26 | 2020-10-27 | 新疆医科大学 | 用于制备治疗子宫肌瘤药物的活性成分及其应用 |
US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101091890A (zh) * | 2007-07-26 | 2007-12-26 | 沈阳药科大学 | 一种复合型乳化剂及用其制备的乳剂及其制备方法 |
CN101810577A (zh) * | 2010-05-06 | 2010-08-25 | 山东大学 | 治疗肿瘤的棉酚静脉注射脂肪乳剂 |
-
2011
- 2011-11-09 CN CN 201110350867 patent/CN102525954B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101091890A (zh) * | 2007-07-26 | 2007-12-26 | 沈阳药科大学 | 一种复合型乳化剂及用其制备的乳剂及其制备方法 |
CN101810577A (zh) * | 2010-05-06 | 2010-08-25 | 山东大学 | 治疗肿瘤的棉酚静脉注射脂肪乳剂 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103202808A (zh) * | 2013-05-03 | 2013-07-17 | 西安电子科技大学 | 一种一锅法制备多功能棉酚纳米制剂的方法 |
CN103202808B (zh) * | 2013-05-03 | 2015-08-12 | 西安电子科技大学 | 一种一锅法制备多功能棉酚纳米制剂的方法 |
US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
US11609042B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
US11740019B2 (en) | 2019-03-14 | 2023-08-29 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
US11747082B2 (en) | 2019-03-14 | 2023-09-05 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
CN111821288A (zh) * | 2020-05-26 | 2020-10-27 | 新疆医科大学 | 用于制备治疗子宫肌瘤药物的活性成分及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102525954B (zh) | 2013-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102512404B (zh) | 一种姜黄素类化合物肺靶向制剂及其制备方法与应用 | |
CN102525954B (zh) | 左旋棉酚及其醋酸盐的注射用冻干乳制剂 | |
CN102579341A (zh) | 一种多西他赛固体脂质纳米粒及其制备方法 | |
CN102805730A (zh) | 神经酰胺脂质体及其制备方法和用途 | |
CN104042567A (zh) | 一种蛇葡萄素纳米胶束及其应用 | |
CN101391098B (zh) | 一种蜂毒素脂质体制剂及其制备方法 | |
WO2019006741A1 (zh) | 一种白头翁皂苷b4的注射用制剂 | |
CN110870868A (zh) | 包含亚甲蓝类染料、营养素或/和抗肿瘤化合物的药物组合物及其应用 | |
CN102397237B (zh) | 一种替米考星胶束制剂及其制备方法 | |
CN101229131B (zh) | 具有降低喜树碱类药物胃肠毒性的新型纳米微粒制剂 | |
CN101108872B (zh) | 植物生物碱提取物及其制剂与用途 | |
CN103040910A (zh) | 一种鹿瓜多肽脂质体注射剂 | |
US9393230B2 (en) | Pharmaceutical composition on the basis of phyto-nutrients with increased bioavailability, having anti-tumor activity, and method for producing said composition (alternatives) | |
CN104856944A (zh) | 阿魏酸冰片酯注射剂 | |
JPH10158156A (ja) | 抗腫瘍剤 | |
CN115120611B (zh) | 一种no供体型胶束组合物及其制备方法与应用 | |
CN105012234A (zh) | 一种二甲氧基姜黄素聚合物胶束及其制备方法与医药用途 | |
CN102144979B (zh) | 用于治疗肿瘤的左旋棉酚或其醋酸盐的注射用冻干粉制剂 | |
CN110870858A (zh) | 包含有机酸酸化剂和常规无效化合物的药物组合物及其应用 | |
CN105796495B (zh) | 一种盐酸伊立替康脂质体药物组合物及其制备方法 | |
CN111465389B (zh) | 多西他赛共缀物的药物组合物及制备方法 | |
CN101491518B (zh) | 一种用于治疗肿瘤的组合物 | |
CN102138916B (zh) | 用于治疗肿瘤的左旋棉酚或其醋酸盐的环糊精包合物 | |
CN105012241B (zh) | 一种高稳定性氯羟吡啶固体分散体 | |
CN108186699A (zh) | 一种具有抗疲劳功效的中药提取物滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200114 Address after: 271100 building 12, pharmaceutical industrial park, Kouzhen, Laiwu District, Jinan City, Shandong Province Patentee after: Shandong peptide Biological Pharmaceutical Co.,Ltd. Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 Patentee before: Jinan Huantai Medical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231124 Address after: 274100 Central Business District, Changjiang East Road, Luxi New District, Heze City, Shandong Province 266, Modern Pharmaceutical Port Patentee after: Dahe Pharmaceutical Technology (Shandong) Co.,Ltd. Address before: Building 12, Pharmaceutical Industry Park, Kouzhen, Laiwu District, Jinan City, Shandong Province, 271100 Patentee before: Shandong peptide Biological Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |